Low HDL Polygenic Risk Score

Some people work hard to keep their HDL cholesterol healthy and still end up with a stubbornly low number. Often the reason is written into their DNA, not their diet or workouts. This test reads that hidden layer by combining many small genetic differences across your genome into a single score that reflects how strongly your biology is pushing your HDL down.

Knowing this score early matters because low HDL travels with insulin resistance, fatty liver, metabolic syndrome, and a higher chance of heart attack and stroke. If your genetics are nudging your HDL down, the practical question is not whether you can fix the genes but how aggressively you should monitor the downstream numbers and act on them.

What This Score Actually Reads

HDL particles are tiny shuttles built mostly from a protein called apoA1, made in your liver and intestine. They pick up extra cholesterol from cells throughout your body, including the immune cells that build up in artery walls, and return it to the liver for disposal. This recycling job is called reverse cholesterol transport.

A low HDL polygenic risk score (PRS) sums many common DNA differences in genes like CETP, APOA1, ABCA1, and LPL that, together, set how efficiently your body builds and uses HDL particles. Depending on the platform, a score can draw on anywhere from dozens to millions of variants. No single variant matters much on its own. The combined burden is what shifts your lifetime HDL level.

Studies in people with unusually low or high HDL find that this kind of polygenic load explains a sizable fraction of cases. About 13 percent of people with extremely low HDL and 19 percent of people with extremely high HDL carry an unusually high polygenic score even when no single rare mutation can be found, and these polygenic effects are detectable from childhood through midlife.

Heart Disease Risk

Low HDL is one of the long-standing fingerprints of cardiovascular risk. Genetic and observational evidence both link a low-HDL profile to a higher chance of heart attack and stroke, especially when it travels with high triglycerides.

In an Israeli cohort of about 5,584 adults, people who carried high polygenic risk scores for both low HDL and high triglycerides had roughly 44 times the odds of cardiovascular disease compared with people who had favorable scores on both. Looking at the sexes separately, men and women in the high-risk combination had about 97-fold and 10-fold higher odds of cardiovascular disease, respectively. These are extreme numbers tied to the worst genetic combinations in a relatively small cohort, and they are far larger than the 1.3- to 4-fold differences typically seen between top and bottom risk groups in larger polygenic score studies. The general direction, that the inherited HDL profile is not cosmetic, is consistent across the literature even if the exact magnitudes are not.

Whether HDL itself causes heart disease, or just travels with the things that do, is still being debated. Some Mendelian randomization analyses (a method that uses genetics to test whether a risk factor truly causes an outcome) link higher genetically determined HDL to lower atherosclerosis risk, while others find the HDL signal disappears after accounting for LDL and triglycerides. The American Heart Association's view is that the causal role of HDL in cardiovascular disease is not yet established and that HDL polygenic scores on their own have limited use for predicting heart disease. What is clearer is that LDL, total cholesterol, and triglycerides do appear to be causal drivers, and a genetically low HDL often sits inside a broader atherogenic profile that includes them.

Insulin Resistance, Diabetes, and Fatty Liver

Low HDL rarely arrives alone. It clusters with high triglycerides, central body fat, and rising blood sugar. The triglyceride-to-HDL ratio is itself a marker of insulin resistance, and the same genetic signals that lower HDL also raise risk for diabetes, hypertension, nonalcoholic fatty liver disease, and ischemic heart disease in UK Biobank work involving more than 450,000 participants.

In a Korean study of about 70,614 adults, people in the top group of a body mass index polygenic score had about double the risk of obesity and modestly higher odds of low HDL cholesterolemia. If your genetics already push HDL down, an upward drift in weight tends to push it down further.

Infection and Sepsis

HDL particles do more than ferry cholesterol. They bind and neutralize bacterial fragments in the blood, acting as part of your innate immune defense. A UK Biobank analysis found that a one millimole-per-liter genetically determined increase in HDL was associated with a hazard ratio of 0.84 for infectious disease, meaning roughly 16 percent lower risk per unit of higher HDL. Higher genetic HDL was also linked to better 28-day survival after sepsis.

The signal is not unanimous. A separate hospital cohort confirmed that measured low HDL went with worse sepsis outcomes but did not find that an HDL polygenic score predicted sepsis death, arguing against a strong causal link in that specific setting. The fair reading is that low HDL is at least a marker of vulnerability to serious infection, and possibly a contributor.

Why a Normal Lipid Panel Does Not Cancel This Out

A polygenic risk score is a summary of inherited tendency, not a snapshot of today's cholesterol. Two people can have identical HDL numbers on a standard panel today and very different lifetime trajectories. Someone with a high low-HDL PRS may have an HDL that looks acceptable at age 30, drifts down through their 40s, and crashes during weight gain or pregnancy, while someone with a favorable score can absorb the same life changes with much smaller swings.

The score also predicts how genetic variation moves with you across the lifespan. A long-running Finnish cohort showed that lipid genetic scores predict HDL, LDL, and triglyceride levels at every age studied. The separation between low- and high-risk groups was visible from childhood through midlife, though the strength of the HDL signal weakened modestly with age.

Lifestyle Still Matters With High Genetic Risk

Inherited risk is not destiny. In a Korean study of more than 58,000 adults, the strength of the genetic signal for low HDL was modified by energy intake, smoking status, dietary glycemic index, and sulfur-microbial dietary patterns. In a separate study of 8,314 Koreans, people with the highest genetic risk for low HDL who ate lower-carbohydrate diets had the lowest prevalence of low HDL cholesterolemia. Genetics set the baseline. Behavior sets the slope.

Why This Is a One-Time Test

Your polygenic score will not change. The DNA variants that make it up are inherited at conception and remain identical for life. There is no value in repeating the polygenic score itself unless a different laboratory method is being used to confirm a borderline result.

What does need ongoing tracking is the downstream phenotype: your actual HDL cholesterol, triglycerides, ApoB (apolipoprotein B, the protein that marks every artery-clogging particle), fasting glucose, HbA1c (hemoglobin A1c, a three-month average of blood sugar), and waist circumference. If your low HDL PRS is elevated, get a baseline lipid and metabolic panel now, repeat in 3 to 6 months if you are making lifestyle changes, and at least annually thereafter. The value of the genetic test is in setting the cadence and intensity of the rest of your monitoring.

What to Do With an Elevated Score

If your low HDL PRS comes back in a high range, the next step is not to retest the genetics. It is to get a more complete read on the lipid and metabolic phenotype the score predicts. Order a full lipid panel that includes ApoB and triglycerides, plus fasting insulin, glucose, and HbA1c. If those numbers are already shifting in the wrong direction, the genetic finding raises the urgency of acting earlier rather than later.

An elevated score combined with borderline lipids or rising blood sugar is a reason to involve a lipidologist or preventive cardiologist sooner rather than at the moment a diagnosis is made. It is also worth letting first-degree relatives know, since they share roughly half of your genetic variation and may carry a similar risk pattern without realizing it.

When Results Can Be Misleading

Polygenic scores have specific limitations the reader should understand:

• Ancestry mismatch: Most lipid polygenic scores were built using data from people of European ancestry, and their predictive performance is meaningfully lower in non-European populations. A score that looks accurate in one group can underperform in another.
• Variant panel coverage: The assay only weights the specific variants it was designed to measure. A result described as average does not rule out rarer large-effect mutations elsewhere in HDL-related genes.
• Score scaling differences: Different labs use different reference populations and weighting methods. A high score from one lab may not correspond exactly to a high score from another, which is why standardized clinical cutpoints do not yet exist.
• Genetics is not destiny: Carrying a high-risk score does not guarantee you will have low HDL or develop heart disease. It shifts the probability, not the outcome.

The Honest State of the Evidence

Polygenic risk scores for lipid traits are still an emerging tool. They do not yet have universally agreed-upon thresholds, and routine clinical use lags behind the research. Whether HDL itself is a causal driver of heart disease, or mostly a marker that travels with the real drivers, also remains an open question in the field. That said, the score gives you something a single lipid panel cannot: a sense of where your biology has been pointing your whole life. Used alongside standard testing rather than instead of it, an HDL polygenic score helps you decide how seriously to take the rest of your numbers and how early to start acting on them.